Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 6/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102772 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5106288 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL20155456 | 0.76 | PTGS2 (0.61) | PTGS2PTGS1BRD4BRD2BRD3 | |
| SCHEMBL5106300 | 0.75 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL5114766 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1BRD4 | |
| SCHEMBL5105676 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5108827 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15067969 | 0.72 | PTGS2 (0.56) | PTGS2PTGS1BRD4BRD2BRD3 | |
| SCHEMBL15067648 | 0.72 | PTGS2 (0.56) | PTGS2PTGS1BRD4BRD2BRD3 | |
| SCHEMBL30306252 | 0.72 | EPAS1 (0.71) | PTGS2PTGS1BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410994-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-08-10 | — | — | US | disclosed |
| US-7074939-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1438289-B1 | INDOLE DERIVATIVES AS COX II INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6872744-B2 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1438289-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-07-21 | — | — | EP | disclosed |
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC | 2003-07-10 | — | — | US | disclosed |
| WO-2003029212-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 4/4885PTGS1 3/4885BRD4 1004/4885 |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885BRD4 487/4885 |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885BRD4 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.